Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Sarepta Therapeutics (SRPT)

Sarepta Therapeutics: Chief Technical Operations Officer Bilal Arif's employment to end Sept. 16

Neutral Impact 3 of 5 leadership Written later

Sarepta Therapeutics said Bilal Arif, its Executive Vice President and Chief Technical Operations Officer until August 12, 2025, will leave the company as part of a strategic restructuring and pipeline prioritization. He will serve as a consultant through December 31, 2025, and the filing gives a $576,700 severance payment and a $400 hourly consulting fee.

Key points

  • Employment ends effective September 16, 2025; Arif serves as Special Advisor to the President until then
  • Separation and Consulting Agreement dated August 12, 2025, with consulting through December 31, 2025
  • Severance lump sum of $576,700 and consulting fee of $400 per hour
  • Outstanding equity awards as of August 12, 2025 continue to vest during his employment or consulting period

The filing

CompanySarepta Therapeutics (SRPT)
Form8-K, current report
Filed with the SECAug 13, 2025, 4:10 PM ET
Accession number0001193125-25-179819

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.